ABK Biomedical: Funding, Investors & Team (Sep 2026)
Founded in 2012, we are focused on researching, developing, and commercializing breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. With our multi-disciplinary experience in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination we are staffed with the talent to drive the next level of technology for personalized healthcare in oncology.
ABK Biomedical has raised $91.1M across 3 funding rounds on record, the most recent a Series D of $35.0M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ABK Biomedical Company Profile and Key Stats
Latest funding round on record: Oct 2025.
ABK Biomedical Funding Rounds
ABK Biomedical raised $30.0M in a Series C announced in Dec 2022.
2.4 years later, an undisclosed round of $26.1M was announced in May 2025.
5 months later, a Series D of $35.0M was announced in Oct 2025.
ABK Biomedical Founders and Leadership Team
No contact details are on record for this team yet.
ABK Biomedical Funding Compared to Other Biotechnology Startups
ABK Biomedical's latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ABK Biomedical in Biotechnology and Halifax
Companies Similar to ABK Biomedical
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
ABK Biomedical Funding FAQs
What does ABK Biomedical do?
Founded in 2012, we are focused on researching, developing, and commercializing breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. With our multi-disciplinary experience in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination we are staffed with the talent to drive the next level of technology for personalized healthcare in oncology.
How much funding has ABK Biomedical raised?
ABK Biomedical has raised $91.1M across 3 rounds on record. The most recent is a Series D of $35.0M announced in Oct 2025.
When did ABK Biomedical last raise funding?
ABK Biomedical's most recent funding round on record is a Series D of $35.0M, announced in Oct 2025.
Who founded ABK Biomedical?
FundedIQ lists Sharon Kehoe (Founder) at ABK Biomedical.
Who is the CEO of ABK Biomedical?
Michael Mangano is listed as CEO at ABK Biomedical.
Where is ABK Biomedical headquartered?
ABK Biomedical is based in Halifax, Nova Scotia, Canada.
How many employees does ABK Biomedical have?
ABK Biomedical is in the 11-50 employee band.
How does ABK Biomedical's funding compare to other Biotechnology startups?
ABK Biomedical's latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ABK Biomedical Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ABK Biomedical is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.